FORE Biotherapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced that the Company will participate at the following investor conferences:

Wells Fargo 21^st Annual Healthcare Conference. The Company will attend and participate in one-on-one meetings on Tuesday, September 8.

Morgan Stanley 24^th Annual Global Healthcare Conference. The Company will attend on Tuesday, September 15, and will provide a corporate presentation at 7:45 a.m. ET.

Management will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394 or PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1^st and 2^nd generation BRAF inhibitors. For more information, please visit www.fore.bio or follow us on X and LinkedIn.

Contacts

Investors and Media:

Argot Partners
212.600.1902 | ForeBio@argotpartners.com

Industry:

More News From FORE Biotherapeutics

FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that following the first of two pre-specified interim efficacy analyses for the FORTE basket study evaluating plixorafenib as a monotherapy in patients with advanced solid tumors with BRAF fusions, including recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, the Independent Data Monit...

FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced the closing of an upsized Series D-2 extension financing of $67.4 million, bringing the total Series D-2 amount raised to $110 million. The financing was co-led by SR One, Medicxi, and SymBiosis and supported by a syndicate of new investors, including TaiAx, LG Technology Ventures, Primer Ventures and Axil, and all existing i...